Merck’s Covid-19 pill was no better than placebo in lowering the risk of hospitalization; Biogen eyes former J&J exec as CEO candidate

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

STAT+: Merck's Covid-19 pill was no better than placebo in lowering the risk of hospitalization By Ed Silverman Merck The study failed to reach an outcome that was used last year by regulators – such as those in the U.S. and U.K. — to authorize the medicine. Read More STAT+: Biogen CEO search focuses on scientists, with former J&J exec as a leading candidate By Matthew Herper and Adam Feuerstein and Damian Garde Venrock Mathai Mammen, who until recently was the head of R&D at pharmaceutical giant Johnson & Johnson, would be a departure for Biogen. Read More Sponsor content by STAT Reports Our latest STAT Report: Health care's big bet on blockchain It's not just Bitcoin. In the fiercely competitive world of health care, blockchain technology is quickly becoming the next frontier. But unless you're a cryptocurrency aficionado, diving into the blockchain world and understanding the opportunities it opens up for the health care sector can be daunting. Think of our latest report as your guide to health care's big bet on blockchain. Purchase the report now. STAT+: Up and down the ladder: The latest comings and goings By Ed Silverman Alex Hogan/STAT From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. Read More STAT+: Medicare Advantage quality ratings plunge as government resets to pre-pandemic standards By Bob Herman Adobe The lower quality ratings will drain billions of dollars in bonuses that flow to health insurers that get high marks for the plans. Read More Friday, October 7, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser